Vimarsana
Biggest News Aggregation in the World

Month Prevalence News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Month Prevalence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Month Prevalence Today - Breaking & Trending Today

Why smartphones must be forbidden until the age of 16 - Vimarsana News

Why smartphones must be forbidden until the age of 16

As a clinical psychologist, I have been fighting on the front lines against teen suicide for a decade, and I have seen how the abuse of screens causes young people to miss out on life-coping skills, and deteriorates their mental health

Source: elpais.com
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101 - Vimarsana News

NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101

NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets

What People with Bipolar I Disorder Want You to Know - Vimarsana News

What People with Bipolar I Disorder Want You to Know

(BPT) - Sponsored by Alkermes, Inc.

Alkermes plc: Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness - Vimarsana News

Alkermes plc: Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness

- LYBALVI Demonstrated Less Weight Gain Compared to Olanzapine in Patients With Schizophrenia, Schizophreniform Disorder or Bipolar I Disorder - DUBLIN, Feb. 8, 2022 /PRNewswire/ -- Alkermes

Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness - Vimarsana News

Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-Early, a phase 3b study that evaluated the effect of...